ReviewEuropean journal of clinical pharmacology2026
Identification of potentially heat-vulnerability increasing drugs - a narrative review.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVulnerability to heat-related illnesses may be increased by certain drugs due to various mechanisms. Whereas in articles only rough classifications of heat-vulnerability increasing drugs (HVID) are mentioned, a detailed compilation of suspected HVID is still missing. Aim of the study was to identify HVID.
methodsUsing data from the literature, potential HVID were searched. The evidence for increasing heat-vulnerability, based on PubMed research, was rated as „high“, „possible“ or „unlikely“ by 3 investigators, independently and blinded to the others’ results.
resultsThe initial search retrieved 572 potential HVID. After analyzing 27 trials in healthy subjects, 25 cohort-studies, 19 case-reports, 14 reviews, 7 prospective trials in patients and 4 pharmacovigilance-studies, the evidence to increase heat-vulnerability was assessed as “high” for 110, “possible” for 390 and “unlikely” for 72 drugs. Drugs for the nervous-system, cardiovascular-system and alimentary-tract were most frequent. Hypohidrosis (n = 127), disturbed thermoregulation (n = 35) or skin-circulation (n = 15) and dehydration (n = 10) were frequent mechanisms. Outcome events in cohort-studies were heat-illness/dehydration (n = 10), causes of death (n = 5), heat-related hospital admissions (n = 4), heat-stroke (n = 4), drug-overdose in heat-periods (n = 1) and hypohidrosis (n = 1). Comedication, when reported, disclosed additional HVID in all patients. Conflicting results about heat-vulnerability properties were found for 10 HVID.
conclusionKnowledge about HVID and their clinical relevance is limited. The quality of data is poor and derives mainly from young and healthy subjects. The outcome events are heterogeneous. Interdisciplinary research involving pharmacologists, physicians of different disciplines, pharmacists and health-care workers is needed to create and evaluate plans about modification of drug-therapy during heatwaves.
Indexed as
Identifiers
41968235What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.